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AN EXAMINATION OF OPIOID PRESCRIBING POLICY AND CLINICAL 
PRACTICE IN THE CONTEXT OF THE UNITED STATES OPIOID CRISIS 
In 2017, the United States government declared that the opioid epidemic was a 
public health emergency. Among responses to address the epidemic, the Centers for 
Disease Control and Prevention released a set of opioid prescribing guidelines for 
primary care clinicians. Since their release, federal agencies and experts have been 
interested and concerned about their application in policy and clinical practice.  
This dissertation examines how some of these federal recommendations were 
implemented in clinic practice and state law, as well as the effects of related prescribing 
laws. This dissertation includes three studies 1) a qualitative analysis of clinician and 
patient discussions about opioid-related risks, benefits, and treatment goals, 2) a policy 
surveillance study of state tapering laws and their consistency with the CDC guideline’s 
opioid tapering recommendations, and 3) an empirical study of the effects of morphine 
milligram equivalent daily dose laws and acute opioid prescribing laws on pain 
medication prescribing for patients with Medicaid.  Overall, this dissertation attempts to 
understand the translation of national opioid prescribing guidelines into policy and their 
effects on healthcare delivery.    
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Pain Care in the United States 
“To have pain is to have certainty; to hear about pain is to have doubt.”(1) 
– Elaine Scarry 
Pain is a subjective experience but provides meaningful information to the 
individual. In the United States, an estimated 50 million American adults experience 
chronic pain which is defined as daily pain lasting at least six months (2). As an 
unavoidable part of life and healthcare delivery, pain was expected and often only 
addressed in acute situations (3). Prior to the 1990’s, opioids were infrequently prescribed 
for chronic pain (3). Opioids including Percocet and Vicodin were accepted as too risky 
for pain treatment and highly addictive (4). However, much of that sentiment started to 
change in the late 1990’s when the Joint Commission was funded by the Robert Wood 
Johnson Foundation to develop pain standards (5). The Joint Commission, the American 
Pain Society, and other medical groups began promoting pain as the fifth vital sign and 
suggesting that opioids were a safe way to manage it (5, 6). As a result, opioid 
prescribing jumped from 2 to 8 million prescriptions from the early 1990’s to 1996 (7). 
This number continued to climb until 2012 with a staggering 259 million prescriptions 
(8).  
Due to high prescribing rates (8), by 2017 nearly 218,000 people had an overdose 
related to a prescription opioid (9). Further, an estimated 1.9 million were abusing or 
dependent on opioids based on the DSM-IV diagnosis criteria (10). From 1999-2013, 
opioid use disorder alone accounted for an estimated $72.4 billion in economic burden 
(11).   
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The United States’ Response to the Opioid Crisis 
Policies and Overdose 
In 2016 the Centers for Disease Control and Prevention (CDC) released a set of 
opioid prescribing recommendations for managing chronic, noncancer pain in primary 
care. The CDC Guideline sought to help primary care clinicians make informed decisions 
related to opioid prescribing for chronic pain and acute pain episodes.  
Since the CDC Guideline was published, many states have implemented laws and 
policies to curb opioid prescribing rates. These laws include prior authorizations, pill mill 
laws, prescription drug monitor program use, morphine milligram equivalent limits, and 
daily opioid prescribing limits for acute pain (12-15). 
After acknowledgment as a public health crisis by the United States government, 
opioid prescribing rates fell after 2012 (16). Some state policies have been effective at 
reducing prescribing rates (12, 17, 18). However, as prescribing rates fell, the overdose 
death rates from all opioids did not fall with them (16). According to the CDC, overdose 




As a result of national interest in treating pain, an estimated 10 million patients 
are prescribed long-term opioid therapy (LTOT) (19). Although chronic pain has been 
managed over the last few decades with opioid therapy, there is little evidence supporting 
the benefits of long-term therapy and several risks associated with its use (20). In 
response to recent evidence and the CDC guideline, clinicians have been encouraged to 
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prescribe when medically appropriate and continue opioid therapy when the benefits 
outweigh the risks. However, if benefits do not outweigh risks, clinicians should consider 
slowly lowering a patient’s opioid medication through a tapering process. Opioid tapering 
and discontinuation happen for a variety of reasons. The majority of discontinuations 
result from aberrant behaviors (21); however, discontinuations also occur for pain 
resolution, inadequate analgesia, adverse effects, and for unknown reasons (22). 
And on average, pain does not get worse after discontinuation of LTOT and may 
actually improve pain scores (23, 24). However, experts are also concerned that 
inappropriate discontinuation of LTOT might be contributing to rising illicit drug use.  
The CDC, Federal Drug Administration, and clinical experts believe clinicians and 
policymakers may be misapplying aspects of the CDC guideline in clinical practice (25). 
Their concerns center around opioid tapering, populations targeted for tapering, and hard 
opioid prescribing policy limits driving medical decision making.  Some of the CDC 
recommendations have been criticized for potentially discouraging clinicians from 
prescribing opioids when medically appropriate and inadvertently influencing clinicians 
to abruptly taper prescribing for patients receiving opioids (26). Abrupt tapering places 
patients at risk of experiencing serious withdrawal, psychological distress, uncontrolled 
pain, and potentially, suicide (26, 27). To address whether misapplication occurs, I will 
examine how clinicians and policymakers’ actions compare to the expected actions of the 





Overview of Dissertation 
 This dissertation addresses how clinicians and policymakers are incorporating the 
CDC guideline recommendations into practice to deliver safer pain care. I will explore 
three relationships to address different aspects of how the CDC guideline has been 
translated into practice. Specifically, I evaluate how pain care recommendations effect 
healthcare delivery in office visits, in state law and policy, and pain medication 
prescribing rates. The chapters will focus on five of the CDC guideline 
recommendations: 1) clinicians should establish treatment goals with all patients, 
including realistic goals for pain and function, 2) before starting and periodically during 
opioid therapy, clinicians should discuss with patients known risks and realistic benefits 
of opioid therapy, 3) if benefits do not outweigh harms of continued opioid therapy, 
clinicians should optimize other therapies and work with patients to taper opioids to 
lower dosages or to taper and discontinue opioids, 4) clinicians should use caution when 
prescribing opioids at any dosage, should carefully reassess evidence of individual 
benefits and risks when considering increasing dosage to ≥50 morphine milligram 
equivalents (MME)/day, and should avoid increasing dosage to ≥90 MME/day or 
carefully justify a decision to titrate dosage to ≥90 MME/day, and 5) when opioids are 
used for acute pain, clinicians should prescribe the lowest effective dose…three days or 
less will often be sufficient; more than seven days will rarely be needed.   
Chapter two will describe how clinicians discuss risks, benefits, and goals around 
opioid-related pain care. Chapter three will describe how accurately tapering 
recommendations were translated into state policy. Chapter four will evaluate the effect 
of hard limit laws on opioid prescribing rates.  
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More specifically, chapter two will provide context for how clinicians incorporate 
aspects of the CDC guideline in their discussions with patients. I will use qualitative 
methods to identify emerging themes from primary care visits with clinicians and their 
patients receiving opioid therapy. I will focus on how clinicians and patients discuss 
setting goals and the risks and benefits of opioid therapy.  I will also identify the ways in 
which these recommendations come about and how clinicians and patients discuss them.  
Chapter three will examine opioid tapering state policies and compare them to the 
recommendations set by the CDC guideline. To do so, I will use policy surveillance 
methods to capture and code these policies. I will code policy characteristics and compare 
these relative to recommended tapering guideline attributes. This chapter will describe 
policy variation across states and identify ways in which policies do or do not match 
recommended practices.    
Chapter four will evaluate the effect of recent state policies on pain medication 
prescribing rates. I will use a quasi-experimental design to estimate the effect of 
morphine equivalent daily dose (MEDD) and acute pain limit policies on opioid 
prescribing for Medicaid patients. This chapter will provide a rigorous evaluation of these 
two opioid prescribing policies on opioid and nonopioid medication rates. The results 
will assist future researchers in addressing whether these policies reduce opioid 
prescribing rates and how these types of policies may influence nonopioid medical 
treatments prescribed in vulnerable populations.    
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CHAPTER TWO 
An analysis of primary care clinician communication about risk, benefits, and goals 
related to chronic opioid therapy 
 
Introduction 
Chronic pain and opioid use disorder present enormous public health challenges 
to the United States (US) healthcare system. Estimates of chronic pain prevalence range 
from 25 to 100 million US adults (28, 29). Pain contributes an estimated $600 billion in 
healthcare costs and lost worker productivity annually (29). Between 1999 and 2015, 
healthcare providers quadrupled their prescribing of opioid pain relievers, while overdose 
deaths increased dramatically (30). In 2017, over 47,000 people died in the US from 
opioid overdoses (31). Importantly, primary care clinicians prescribe nearly half of all 
dispensed opioid prescriptions (32). To help combat opioid-related risks, the Centers for 
Disease Control and Prevention (CDC) published the 2016 Guideline for Prescribing 
Opioids for Chronic Pain that targets primary care treatment of chronic noncancer pain 
(33).  
Reflected in the CDC Guideline and other opioid prescribing best practices is the 
need for clinicians to regularly assess, and talk with their patients about, opioid-related 
risks, benefits, and treatment goals when considering or managing chronic opioid 
therapy.  However, because primary care clinicians are often caring for multiple patient 
conditions during short clinic visits (34-36), it is unclear how accurately or 
comprehensively clinicians discuss opioid-related risks, benefits, and goals with their 
patients. At the same time, accurate and comprehensive communication is important to 
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ensure that patients understand opioid-related health risks and benefits, and that clinicians 
and patients have a common understanding of appropriate treatment goals. Indeed, prior 
research has found that patients may have inaccurate perceptions of opioid-related risks 
and benefits (35, 37), and patients and clinicians may not share the same outcome goals 
(38).  
Given the importance of effective primary care communication to achieve safe 
and guideline-concordant opioid prescribing, the purpose of this study was to describe 
how clinicians communicate about risks, benefits, and goals of opioid therapy during 
primary care visits. This knowledge may help identify communication deficits in patient-
clinician interactions about opioid-related risks, benefits, and goals of opioid therapy. 
This knowledge may also aid in developing policy, education, and other interventions 
that increase safe and patient-centered pain care. 
 
Methods 
We conducted an observational study that analyzed audio recordings of clinic 
visits between primary care clinicians and patients with chronic noncancer 
musculoskeletal pain who were receiving opioids. This study, which focuses on patients 
receiving opioids, is part of a larger study to understand clinical decision making for 
chronic pain care, including care that does not involve opioids. We analyzed clinic visits 
occurring between May 2016 and May 2017. The Indiana University Institutional Review 




Population and Sample 
We recruited primary care clinicians from 3 healthcare systems in Indiana and 
Illinois. Eligible clinicians included physicians, physician assistants, and nurse 
practitioners who prescribe opioids. We purposefully recruited participants to obtain a 
sample that was diverse in practice type and location, clinician age, race/ethnicity, and 
sex. We also sought to have a diverse representation among the patients, including 
variations in age, race/ethnicity, sex, and complexity of pain condition. We recruited 
clinicians using e-mail invitations, in-person presentations at clinic staff meetings, and 
word-of-mouth. Next, we identified patient participants based on medical record review 
and recommendations from recruited clinicians. We deliberately sought patient diversity 
by recruiting from health clinics that serve diverse patient populations. Eligible patients 
were required to speak English, have a current chronic musculoskeletal pain condition, 
have no history of cancer in the 3 years before their visit, and currently receiving opioids. 
Because the larger study also recruited patients not currently receiving opioids, we 
identified patients with current opioid prescriptions by reviewing transcripts of their 
clinic visits.  
Before we approached the patients, their primary care clinician confirmed their 
eligibility as a patient with chronic noncancer musculoskeletal pain. Both clinician and 
patient participants provided written informed consent to participate in the study. Patient 






After notifying their primary care providers, a member of the research team 
approached eligible patients in clinic waiting areas or the exam room before scheduled 
visits. Patients were given sufficient time to read the consent form and ask any clarifying 
questions of the recruiter. After obtaining informed consent, the researcher placed an 
audio recorder in the exam room to capture all auditory interactions between the patient 
and primary care clinician. After the visit, the audio recorder was removed, and the audio 
file was transferred to a secure computer server. Next, a professional transcriptionist 
transcribed the audio recordings. Research team members de-identified each of the 
transcripts before analysis. 
 
Analysis 
We used a combination of deductive and inductive analytical approaches to 
explore patterns and themes related to clinicians’ descriptions of risks, benefits and goals 
of opioid therapy during visits with patients (39, 40).  First, to ground the analysis in 
established clinical practice recommendations, we used a deductive or “top-down” 
approach to develop a codebook based on a subset of CDC Guideline recommendations 
that focus on communication about opioid-related risks, benefits, and goals of opioid 
therapy (6). Specifically, the Guideline recommends “… clinicians should establish 
treatment goals with all patients, including realistic goals for pain and function…” 
(Recommendation 1) and “… clinicians should discuss with patients known risks and 
realistic benefits of opioid therapy …” (Recommendation 2). The codebook included the 
following codes: (i) risks – utterances about current or potential for negative health 
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effects of opioids; (ii) benefits – utterances about current or potential positive health 
effects of opioids; and (iii) goals – utterances about desired changes to pain therapy being 
utilized and/or utterances about the intended health effects of using opioids.  
Second, two experienced and trained coders (ED and OM) individually applied the initial 
codes to each clinic visit transcript in Dedoose qualitative analysis software Version 
7.7.6. The coders then met to discuss the fit of the codebook and adjusted codes as 
needed, resulting in a revised coding template. During this process, we also used an 
inductive or “bottom up” approach to describe new categories of meaningful data and 
make modifications to the codebook (40). For example, during this process, we divided 
the benefits code into two parts. The first code captured utterances about the positive 
health effects of opioids. The second code captured utterances about the lack of positive 
health effects of opioids. 
Next, the two coders independently applied the codes from the modified 
codebook. The codes were applied at the utterance level, and codes were not mutually 
exclusive (39). The coders met after the first transcript and periodically thereafter to 
discuss coding differences and reach consensus. After coding all transcripts, each coder 
individually analyzed the coded text for patterns and themes, using the overarching 
research questions as a guide (41). During analysis, the coders met periodically to review 
emerging themes and reconcile any disagreements. We finished collecting and analyzing 
additional transcripts after two rounds of coding. Initially, we included and coded 24 
transcripts. Next, we included 6 additional transcripts to determine whether any new 
themes emerged and if the emerging themes were consistent in the new transcripts. When 
no new themes emerged in the second round of coding, we concluded data collection. 
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Finally, to ensure the analysis captured patients’ responses and interactions with their 
clinicians, we further examined the transcript excerpts within each theme. This process 
generated additional codes focused on patients’ responses. Two coders individually 
identified patient response-related codes, met to compare codes and reach consensus, and 
then applied these codes to all transcripts. The coders met and reviewed each excerpt 
until they reached consensus.   
Throughout data analysis, we used several established qualitative methodology 
procedures to ensure rigor and validity of our findings. Specifically, we practiced 
reflexivity by continually questioning interpretations of data and becoming aware of 
one’s own preconceptions and biases. We also actively sought out the depth of 
description (seeking out rich, particular details of participants’ words), and searched for 
alternative explanations of the data (42-44).  
 
Results  
Overview of Patients, Clinicians, and Visits  
We analyzed 30 clinic visits across 3 health systems, 2 not-for-profit and 1 
academic. The clinic visits took place across 6 clinics, with 21 visits at urban clinics and 
9 at rural clinics. The clinic visits involved 11 physicians and 1 family nurse practitioner. 
Clinicians’ specialty included family medicine (n = 8), internal medicine (n = 3), and 
general medicine (n = 1). Clinicians’ experience ranged from 2 to 30 years of practice. 
Half of the clinicians were female; 9 identified as white, 2 identified as African 
American, and 1 identified as Asian.  
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Twenty of the 30 patient participants identified as female. Several patients had 
multiple pain diagnoses (as reported by their clinician following the visit), with the most 
common diagnoses being osteoarthritis (n = 10), spondylosis (n = 6), low back pain (n = 
5), radiculopathy (n = 5), and spinal stenosis (n = 4). Additional information about study 
participants is located in Table 1.  
Nearly all clinicians had discussions related to risk, benefits, or goals of opioid 
therapy. Discussions included five themes in clinician communication about risks, 
benefits, and goals of chronic opioid therapy. Patient responses to clinician utterances 
generally fell into three main categories: listening, agreeing, and providing or asking for 
more information about a topic. 
 
Communication About Individual-Level and Population-Level Risks  
Clinicians varied in their opioid-related risk utterances, sometimes describing 
individual (i.e., patient-specific) risk factors and/or sometimes describing population-
level risk statistics. A few clinicians described individual-level risk factors and negative 
outcomes associated with opioid use (e.g., comorbid disease or fall risk) specific to the 
patient. In some instances, clinicians described individual-level risk factors as rationale 
for recommending reduction or discontinuation of opioids. In this example, a clinician 
described how a patient’s comorbid condition, chronic obstructive pulmonary disease 
(COPD), when combined with opioids, may increase the severity of respiratory 
suppression:  
Clinician 3: . . . we do not want you on the narcotics a long time. The 
thing that you are getting is one of the side effects is that it can suppress 
breathing. So you already have COPD you have enough trouble breathing 
just with your COPD.  
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Patient 5: I breathe a lot better now that I quit smoking though.  
 
Some clinicians also described opioid-related risks at the population level. For 
example, clinicians referenced current rates of opioid addiction or overdose. These risks 
referred to someone other than the patient. For example, this clinician communicated 
opioid-related mortality statistics:  
Clinician 6: . . . when people are on long-term pain medicine, and things 
are getting tighter and tighter as you know, it is hard because people are 
dying. We have almost 100 people a day dying of narcotic overdose every 
day. It is actually, I have not been able to talk to _____ at the school today 
. . . for years and years, the number one cause of death in teenagers has 
always been car crashes. In the last 6 years, opioid overdose. So teenagers 
in America today are more likely to die of an opioid overdose than a car 
crash.  
 
Patient 18: I do understand that.  
 
In response to individual and population-level risk comments, some patients 
listened to the information provided through short responses to the clinician, similar to 
the quote above. We also saw some patients agreeing and/or requesting additional 
information about the risks as well as providing some of their own information to the risk 
discussion like Patient 5 who has COPD. Patient 5 provides more information about how 
her recent lifestyle change has made it easier for her to breathe. 
 
Communication About Policies or New Practices Related to Opioids  
Some clinicians also described current opioid policies or changes to prescribing to 
their patients. Most of these clinicians worked in the same health care system. In nearly 
all cases, this discussion occurred in the context of opioid dose reduction or 
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discontinuation. For example, this clinician described the CDC Guideline for Prescribing 
Opioids for Chronic Pain and suggested that the patient’s current dose was too high6 :  
Clinician 6: . . . Cause we’re kind of . . . I think I showed you before, the 
CDC came out with some guidelines and we’re kind of exceeding those. 
We’ve got dose . . . of course you’re a big guy and everything like that.  
 
Another clinician described her health system’s policy that recommends limiting opioid 
prescriptions:  
Clinician 3: Now at HEALTH SYSTEM really doesn’t want us writing 
more than 2 pain pills a day. If we said we were going to reduce these 
from 4 to 3, do you think you would still manage or how would that be for 
you?  
 
Patient 5: No that wouldn’t work. That just wouldn’t work. I know we 
talked about that last time.  
 
In most circumstances, clinicians referenced policies or changes in common practice to 
introduce the topic of tapering or as support for the decision to taper. Many patients 
listened to clinicians’ explanations about opioid policies and practices and were 
occasionally not given a chance to respond or confirmed with short responses, such as 
‘‘I’m listening’’ and ‘‘I understand.’’ 
 
Communication About the Limited Effectiveness of Opioids for Chronic Pain Conditions 
Some clinicians described opioids as medications that can reduce pain in the 
short-term but not provide long-term benefit for patients’ underlying pain conditions. 
These utterances often occurred in the context of discussion about nonopioid treatment 
options and/or about identifying the underlying cause of the patients’ pain. For example,  
Clinician 5: The challenge here is making sure we are treating your pain 
with the right medication. Yea the Norco (hydrocodone and paracetamol) 
will make the pain go away, but it will not necessarily treat the cause of 
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the pain, and if we treat the cause of the pain then maybe long term you 
will not have to take [opioids] . . . 
 
Patient 17: Well I’m thinking I might have hurt it lifting her. I still do a lot 
of lifting and she’s [granddaughter] gotten heavier . . .  
 
Similarly, another clinician focused on the importance of understanding the underlying 
cause of pain rather than relying on opioids:  
Clinician 7: You know as far as the pain medication. We need to figure 
out what’s going on. That way we can kind of get at the root cause and 
you know just throwing pills at you is not a good, long-term plan here . . .  
 
Most patients listened or agreed with clinicians’ discussions of limited benefits from 
opioids and in a couple instances mentioned their acceptance that their pain may always 
linger.  
Clinician 8: There’s certain things I’m just not going to be able to fix for 
you and I’m glad that you have that, you know, mind set about it, it 
certainly makes our job a lot easier.  
 
Patient 20: Especially I have a lot of arthritis all over my body and that’s 
the same thing with the fibromyalgia, you just have a lot of pain. I’ve had 
it for 17 years. I guess I just learned to deal with it and pray that I can at 
least stay on the tramadol to help my legs. 
 
Communication About Nonopioid Treatment Options for Chronic Pain  
Many clinicians discussed using nonopioid therapies (e.g., nonsteroidal anti-
inflammatory drugs, topical lidocaine, or physical therapy) as potentially better 
approaches to treating patients’ pain. In the example below, one clinician suggested 
several non-opioid treatment options in addition to not increasing the opioid dose:  
Clinician 7: Instead of just upping what we are already doing actually 
keeping the Norco (hydrocodone and paracetamol) where we are but help 
attack the pain in another way. . . . Lyrica (pregabalin) and gabapentin. 
Physical therapy would be great . . .  
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Some clinicians also suggested additional assessments and consultations to identify the 
root cause of the patients’ pain condition (e.g., imaging or referral to surgery).  
The majority of the patients agreed with or discussed additional information 
during nonopioid treatment discussions. Patients were often onboard with trying new 
medications to treat the pain and sometimes wanted clarification of medication 
administration, logistic information about tapering/receiving these new treatments such as 
transportation, or to share other relevant information. For example, Patient 26 agrees with 
the new treatment plan with the expectation that it will better control her pain.  
Clinician 10: I would be interested to see how a combination of the 
Cymbalta and low dose Lyrica help with things and if that allows us to 
continue our efforts and kind of wean down that Oxycodone.  
 
Patient 26: Yeah, if I can have an alternative that worked better, hey I’m 
in.  
 
In the context of a couple physical therapy discussions, clinicians emphasized the 
importance of pursuing physical therapy to avoid falls and improve physical function. 
Beyond these, functional discussions varied from a short statement at the beginning or 
end of a visit to patients setting goals such as playing with grandkids or going upstairs. 
 
Communication About the Goal of the Opioid Tapering  
Some of the clinicians had discussions about tapering the opioid medications that 
patients were currently taking. Tapering-related utterances ranged from clinicians 
expressing discomfort with a current opioid dose to clinicians directly recommending 
dose reduction. Some of these communications were suggestive of ongoing discussions 
about opioid tapering across several visits. For example, one clinician responded to a 
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patient’s request for an increase in an opioid dose by suggesting opioid tapering and her 
discomfort with the current dose:  
Patient 1: Really I need something better for pain. I really do. If you could 
up my milligram.  
 
Clinician 1: I won’t be able to do that, actually we’re working on 
decreasing it, because you’re on more than I’m really comfortable 
prescribing.  
 
In this example, the clinician recommended nonopioids for pain in support of the 
tapering process:  
Patient 26, Clinician 10: I would be interested to see how a combination of 
the Cymbalta (duloxetine) and low dose Lyrica (pregabalin) help with 
things and if that allows us to continue our efforts and kind of wean down 
that oxycodone.  
 
Most patients agreed with tapering discussions while a couple requested more 
information about the tapering process such as how much they would be going down. 
Clinician 5: So instead of like taking away the 7s and going straight to the 
5s you take them away incrementally.  
 
Patient 11: What are you thinking of this?  
 
Clinician 5: It is a little bit slower, but I think you will feel less of a 
change. 
 
Additional illustrative quotes related to each of the five themes can be found in 
Table 2.  
 
Discussion  
Currently, the United States is facing a public health crisis related to opioid use 
disorder and overdose deaths (30, 45). A significant driver of this crisis has been 
widespread opioid prescribing for pain, a prevalent symptom that affects millions of 
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Americans. Primary care clinicians prescribe more opioids than any other provider type 
(32). Yet primary care clinicians are time constrained during visits (34, 36) and report 
limited pain management knowledge (46). Therefore, this study aimed to describe how 
primary care clinicians communicate with patients about opioid-related risks, benefits, 
and goals. This is an important step in ensuring clinician communication is consistent 
with current clinical guidelines, and in supporting safe prescribing and effective clinician-
patient relationships.  
The primary finding of this study is that clinicians actively communicated about 
opioid-related risks in multiple ways. We observed clinicians explaining to patients that 
increased opioid doses could cause sedation and other adverse effects (20, 47). In some 
cases, clinicians articulated these risks in terms of individual risk factors, such as 
increased risk of respiratory problems in a patient with COPD (48). More often, 
clinicians described population-level risk information, such as opioid-related mortality 
statistics. Clinicians also referenced policies or current practices that recommended 
caution in opioid dosing, which could be interpreted as indirect discussions about risks. 
Similar to prior research, we found that clinicians referenced policies as a facilitator in 
tapering discussions to avoid blame and discomfort when communicating with the patient 
(49). Given that clinical guidelines recommend clinicians actively assess and discuss 
risks, this finding is generally encouraging; however, with recent attention to guideline 
misapplication, this discussion type may be a concern for patients whose risks do not 
outweigh the benefits (25, 50). At the same time, it is unclear if and how different 
approaches to communicating opioid related risks differentially affect patients. The use of 
different risk communication approaches may have implications for clinician satisfaction 
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as well as patient satisfaction, treatment adherence, and health behavior (51, 52). 
Evidence shows that clinicians who tailor their risk communication to a specific patient’s 
case might better inform patients (51-54). For example, a recent study revealed that 
patients preferred to know how opioids may affect their health based on their unique 
medical history, as opposed to population-level concerns (51). Furthermore, more 
accurate patient risk perceptions may aid conversations about therapy changes, such as 
opioid tapering (51). At the same time, when discussing concerns about risks and aiming 
to reduce opioids, a conversation that can be fraught (52, 55-58), clinicians may feel 
more comfortable deferring to a third party policy or rule, which cannot be directly 
negotiated.  
When examining utterances about opioid-related risks from the patient 
perspective, we observed that most of the patients listened to clinicians discussing risks 
without commenting. Some of the patients wanted to have clarifying discussions about 
risks of opioids. Thus, similar to prior research these findings suggest that patients may 
not fully understand or agree that opioid-related risks apply to them (51). Additional 
research is needed to identify barriers that preclude patients from being more actively 
engaged in communication about opioid-related risks with their primary care provider.  
We also found that clinicians communicated about the limited effectiveness of 
opioids in treating chronic noncancer pain, especially for improving general outcomes 
like physical function (20, 59). Such discussions are encouraging given the limited 
evidence for the benefit of long-term opioids in treating chronic noncancer pain (60).  
We also found that many clinicians discussed the use of nonopioid therapies for 
patients’ pain. In some cases, using nonopioid therapies was described in the context of 
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clinicians’ goals to maintain or decrease patients’ opioid doses. While we saw patients 
often agree or listen to the proposed changes to their treatment plan, previous literature 
suggests patients are not confident about managing pain without opioid medication (35). 
This incongruence between patient preferences and utterances during clinic visits has the 
potential to harm patient-clinician relationship and should be explored further.  
 
Limitations 
Although we reached thematic saturation in the analysis, having a larger and/or 
more diverse sample of clinicians might have elicited a wider range of communication 
themes. It is also plausible that patients or clinicians who declined to participate may 
engage in different discussions about opioids than those who volunteered to be observed; 
consequently, we may have missed some aspects of clinical communication and 
perspectives related to risks, benefits, and goals of opioid therapy. Additionally, we did 
not assess the dose, type, duration of opioid therapy, or history of substance use disorder, 
all of which might influence communication about opioid therapy. Also, this study 
occurred in the Midwestern United States, and results may not be transferable to other 
settings. With that said, this region of the country has been particularly affected by opioid 
use disorder, making it an important area to study. We also recognized that clinician 
discussions could have been affected by being audio recorded. However, we believe that 
by using a discreetly placed audio-only recorder, such effects were minimal. Finally, 
because we captured a single visit in an ongoing patient-clinician relationship, we may 
have missed other relevant communication about risks, benefits, and goals of opioid 
therapy. With that said, given the risks and regulations currently surrounding chronic 
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opioid therapy, we believe it is reasonable to expect that some meaningful opioid-related 
communication occurs at all primary care visits.  
 
Conclusion 
This study provides timely understanding of how clinicians communicate with 
patients about common chronic pain conditions and the medications often used in their 
treatment. These findings add to recent literature that aims to conceptually describe 
factors affecting patient-clinician interactions (61) and clinical decision making for 
chronic pain care. (62) Building on this work, future studies might examine larger 
samples of patients and clinicians to estimate the prevalence of the types of 
communication we observed as well as the relative effectiveness of different 
communication strategies. Finally, educational efforts and decision support tools could be 
designed to help clinicians communicate with patients in ways that support safe and 
guideline concordant opioid prescribing while minimizing poor patient experiences. 
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Table 1. Description of the Clinician (N=12) and Patient Samples (N=30)  



































Years of practice 
<10 



































































































*Some patients had multiple pain diagnoses and pain locations. As a result, totals are 
more than the number of patients. 
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Table 2. Emergent Themes with Illustrative Quotes 





Clinician: The problem is how do we get your pain better without 
putting you on medicines that are going to make you feel more 
groggy and also that won't have other long-term side effects and 
make you more likely to fall (Patient 15, Clinician 7) 
 
Now on this pain medicine, like I said, I'm going to give you #20 
just in case you take them and they loop you out, I don't want to 
give you a ton.  So you're probably going to want to call me the 
end of this week, to let me know whether it is working or not 









Clinician: So it can cause lots of side effects, and I can give you a 
whole handout about this, there's the constipation, possible to get 
addictive, confusion, causes people to fall, it can change how your 
body feels pain so actually you have more pain as time goes on... 
so all that stuff. (Patient 15, Clinician 7) 
 
Patient: That's fine, but here's the way I understand opiates for 
people who take them recreationally, they work as a. 
 
Clinician: A stimulant. 
 
Patient: A stimulant, yeah.  So it works like cocaine or 
methamphetamine or something like that. 
 
Clinician: ___ actually a lot of people just want to be numb.  
They want to not feel anything.  They want to be sedated.  That is 
why trazodone, sertraline and Zoloft (Sertraline), seroquel, all of 
these ___ can be abused.  Some people just want to be knocked 
out, you know?  I'm not saying that is what you want, you know, 






Clinician: The ___ policy wants us to cut down on your Norco 
(hydrocodone and paracetamol) / to 2 a day but I’m just gonna say 
you know what, you need your 4 a day.” (Patient 6, Clinician 3) 
 
Clinician: I think the tough thing about chronic pain is that it’s very 
easy to slip out of control, so I'm not someone to write large 
quantities for long periods of time because, you know, if you get a 
big bottle, it’s very easy to just take a lot of them initially and then 










Clinician: So it's important to me that you try again to see if it will 
help your back, because that's really / the underlying thing that will 
help your back.    The pain medicine isn't going to help, it's just 
going to make the pain go away, but it will always be there, unless 
we do something to help. (Patient 1, Clinician 1) 
 
Clinician: “The reason why I'm pushing the ibuprofen is because 
you have some inflammation, you saw it on your MRI right?  And 
this is a medicine that is actually going to help decrease the 
inflammation.  I think that's more helpful, to me, than the Percocet 




Clinician: for your back pain, although you had that for a year, 
we're going to put you right back on your gabapentin which you're 
out of, back on your Flexeril (cyclobenzaprine), ___ pain.   We will 
keep your pain pills where they are right now.” (Patient 8, 
Clinician 3)    
 
Clinician: Okay.  So let's tell you what ___, so a couple of things, 
one for your back pain, although you had that for a year, we're 
going to put you right back on your gabapentin which you're out of, 
back on your Flexeril (cyclobenzaprine), ___ pain.  We will keep 




Clinician: Later on in the month, if things are going well with 
adding the Mobic (meloxicam) and your exercises, maybe you 
could try a half of one [MS Contin] (morphine).  Break it in half 
and see what happens.  Because our goal eventually is to try to get 
you off completely. (Patient 12, Clinician 6) 
 
So one of the things I wanted to talk to you because in the 
meantime we talked about this the last time.  I would like to talk 
about, even though we are talking about this new identified pain, 
cutting back on our pain medications. (Patient 11, Clinician 5) 
Note:  
a Individualized risk discussions occur when a clinician addresses risks specific to that 
patient. 
b Population risk discussions occur when a clinician addresses risks about the general 






Assessing variation in state opioid tapering laws: How do state laws compare with 




In 2017, the United States government declared the opioid crisis a public health 
emergency, identifying prescription opioids as a major contributor (63). During 2017, 
over 47,000 people died from an opioid-related overdose (64) while an estimated $78.5 
billion in economic burden has accrued from prescription opioid overdose, abuse, and 
dependence (65). As one approach to curb these outcomes, the Centers for Disease 
Control and Prevention (CDC) released a set of opioid prescribing recommendations for 
primary care (33, 66). These recommendations sought to provide guidance on when and 
how to prescribe opioids to patients with chronic nonmalignant pain in the primary care 
setting. However, since their release federal agencies have voiced concerns of abrupt 
tapering (26) and caution that misapplication of the guidelines may be occurring in 
clinical practice (25, 50). When patients are discontinued from opioids too abruptly, they 
can experience serious withdrawal, psychological distress, uncontrolled pain, and in some 
cases suicide (26).  As a result, abrupt tapering and discontinuation of opioids may place 
patients at risk of having inadequately controlled pain (26, 60) which could result in 
seeking illicit opioids (67). Given states have enacted recent policies in response to the 
opioid crisis (14, 15), states may also have attempted to address inappropriate tapering. 
Recently, clinical experts identified three components of the CDC guideline that 
could be misapplied by clinicians and thus could contribute to abrupt tapering and 
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inappropriate discontinuation of opioids (25) Specifically, clinical experts raised concerns 
about 1) setting a hard morphine equivalent daily dose threshold (MEDD), 2) setting 
prescription duration limits for acute pain management, and 3) determining when and 
how to taper opioids (25, 50). Since the guideline was released, some states enacted new 
opioid prescribing laws to control prescribing rates and promote safer prescribing 
practices (14, 15, 17, 68). Researchers have examined state policies pertaining to MEDD 
(14) thresholds and those pertaining to prescription duration limits for acute pain (15) and 
generally report variation across states with respect to dose thresholds, duration, and, 
flexibility of clinical judgment to override the policies. No research has examined state 
variability in laws regulating when and how to taper opioids, but some federal (69-71), 
state (72, 73), and provider organizations (74) have published tapering policies and 
guidelines with varying instructional detail and information (69, 70, 72-74). Although the 
CDC guidelines may influence prescribing behavior, clinicians are also likely to be 
influenced by state laws. Thus, an assessment of state laws pertaining to when and how to 
taper opioids is necessary to address rising concerns about guideline misapplication in 
clinical practice. 
The purpose of the current study is to examine state laws that address when and 
how to taper prescription opioids, determine the extent to which such laws vary across 
states, and describe the extent to which such laws are concordant with the CDC guideline 
and the CDC tapering pocket guide.  Further, I will examine how the variability in state 
tapering laws is associated with state characteristics including opioid-related outcomes.  
In order to accomplish these goals, I will use policy surveillance methods (75-77) to 
extract and code tapering laws in each of the 50 US states and the District of Columbia.  
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This assessment will be beneficial to researchers interested in advancing the ongoing 
discussion of guideline misapplication in clinical practice and to policymakers interested 






In this study, I systematically searched state statutes and regulations (heretofore 
state laws) related to when and how to taper opioid prescriptions for chronic, noncancer 
pain in primary care. To identify state laws, I used LexisNexis, an online library database 
comprised of historical records of state laws and cases (78). With LexisNexis, I 
conducted a comprehensive legal search to identify state statutes and regulations related 
to opioid tapering for all 50 states and the District of Columbia implemented prior to 
January 1, 2020. Once identified, I coded these laws for specific attributes to describe and 
compare them to the CDC guideline and the opioid tapering pocket guide. These 
attributes characterize specific aspects of the laws and determine whether they contain 
information recommended in opioid guidelines. Lastly, I evaluated the relationship 
between law attributes and various state characteristics including geographical region, 
population size, political leaning of the governor when the law was enacted, opioid 
prescribing rate, and opioid-overdose rate. I included governor political leaning to 






I defined opioid tapering laws as those pertaining to the reduction and/or 
discontinuation of opioid therapy for patients with chronic pain or receiving long-term 
opioid therapy. I was only interested in laws that targeted chronic pain management in 
primary care, the intended audience of the CDC guideline (33). As a result, to be included 
in the study, three things needed to be true 1) the law could be or was specifically 
applicable to primary care prescribers, 2) the law applied to chronic pain prescribing, and 
3) the law mentions anything related to controlled substance tapering.  
 
Search Strategy 
 I conducted a comprehensive review in LexisNexis to capture statutes and 
regulations related to opioid tapering using the following search strategy: (taper* OR 
discont* OR wean*) and prescri* and (opioid* OR controlled substance OR narco*). All 
polices were reviewed by a trained qualitative researcher (ED), who erred on the side of 
inclusion during this process. The researcher reviewed each state statute and regulation 
identified in the search for inclusion based on the scope set above. Laws pertaining to 
tapering but inconsistent with the intended audience of the CDC guideline were excluded. 
These excluded laws often focused on addiction treatment (e.g., medication assisted 
treatment, opioid treatment programs, office-based addiction treatment, substance abuse 
treatment programs, and addiction co-prescribing), scope of practice, or non-primary care 
settings such as pain clinics, hospice organizations, and skilled nursing facilities. Eight 
states also passed duplicate laws, or laws that use nearly if not identical language. These 
laws would either apply to different prescriber groups or in the treatment of different 
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kinds of pain such as fibromyalgia and lower extremity pain. These duplicate laws were 
recorded but counted as a single law in the sample.   
 
Law Attributes Coded 
I collected standard law attributes based on recently published opioid prescribing 
legal review studies to be consistent with prior policy surveillance work (14, 15). I 
reviewed these papers to identify common characteristics used to describe state laws. 
They included: the state, the type of law, the effective date, contributing authors of the 
law (e.g. state medical board, Medicaid agency, health department, state legislature, 
medical board, pharmacy board, etc.), the number of laws per state, patient and prescriber 
populations included or exempt from the law, and whether the law identifies a penalty for 
noncompliance.  
To measure concordance between states laws and the CDC guideline, I created a 
list of concordance attributes. Concordance attributes were constructed based on tapering 
recommendations from the CDC’s opioid tapering pocket guide and a recently published 
article, from a group of clinical experts in pain and opioids (25, 33, 70).  The experts 
identified three tapering behaviors to consider in clinical application: management of 
inherited patients with a full reevaluation, cautions of abrupt opioid discontinuation, and 
exemption of patient populations beyond the scope of the CDC guideline (25).  
 
Analysis 
A single researcher reviewed and coded states in batches of five to address 
emerging questions with coauthors about inclusion and review code application with a 
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law librarian. For example, the researcher coded a law and reviewed the coded attributes 
with a law librarian for input. This process was repeated until all 50 states and the District 
of Columbia were coded. All state data was recorded in an Excel spreadsheet.  
To further understand the variability in state law attributes, I evaluated the 
relationship between state characteristics and law attributes. I examined five state 
characteristics: geographic region, population size, political leaning of the governor at the 
time the law was enacted, current opioid prescribing rate, and current rate of opioid-
related overdose deaths. Geographic region and population estimates were obtained from 
the US Census Bureau Classifications and Data (80). Political leaning was based on the 
state governor’s political party at the time the law was enacted and was collected from 
the National Governor’s Association (81). Opioid prescribing and opioid-related 
overdose data were collected from the CDC’s National Center for Injury Prevention and 
Control data from 2006 to 2018 and 1999-2018, respectively (66). I categorized state 
population based on percentage of the national population. States with less than 1 percent 
of the US population were small (<3.5 million) and states with 3 or more percent were 
large (≥9 million). Opioid prescribing and opioid-related overdose rates were measured 
annually. To evaluate the relationship between these state characteristics and law 





 As of December 31, 2019, twenty-seven states and the District of Columbia 
enacted 61 laws that mention tapering controlled substances for chronic pain and applied 
to primary care. Nearly half of taper laws were enacted between 2016 and 2019 (n=30 
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laws, see Figure 1). Table 3 presents the frequencies of each law attribute and the states 
that have enacted them. Most laws were regulations (85.2%) and authored by medical 
boards (31.1%), workers’ compensation boards (21.3%), or state health departments 
(14.7%). Sixteen states (31.4%) enacted a law with a penalty for noncompliance 
including lack of reimbursement (n=10 states), disciplinary action (n=5 states), and 
criminal offense (n=1 state). State laws applied to multiple provider types (states=22), 
physicians or medical directors (states=7), and advanced practice registered nurses 
(states=6).  Figure 2 displays a US map of all the states with a taper law. Most states with 
taper laws are in the southern and northeastern regions of the US.  
 In Table 4, state and law frequencies are listed by CDC tapering recommendation. 
Few states have tapering policies that capture recommendations from the CDC’s opioid 
tapering pocket guide. The CDC taper recommendation that is most often represented in a 
state law was for prescribers to weigh the benefits and risks of opioids to make a decision 
about whether to continue, reduce, or discontinue use (67.9% of states with laws). The 
second most common CDC taper recommendation was to taper when the patient shows 
signs of substance use disorder (e.g. work or family problems related to opioid use, 
difficulty controlling use) (28.6% of states with laws). Approximately one-third of states 
with a taper law (35.7%) included at least 1 recommendation about when to taper an 
opioid prescription.  And only four states with a taper law (14.3%) included at least 1 
recommendation about how to taper.  
Table 3 and Table 4 above also include items pertaining to the critical 
recommendations from the expert panel (25). Specifically, three states (10.7% of states 
with laws) included information about inheriting patients and two states (7.1% of states 
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with laws) cautioned about abruptly discontinuing opioid therapy. Over half of states 
(64.3% of states with laws) identified exempt patient groups, patients for whom the law 
does not apply; however, the patient groups identified varied across states and laws, see 
Table 3. Some states (39.3% of states with laws) excluded more than one patient 
population. Whereas a few states only excluded patients with cancer pain (14.3% of 
states with laws) or palliative care (10.7%). Variation also occurred across laws, some 
states with more than one taper law (35.7% of states with laws) enacted laws with 
different exemption groups.  
 In Table 5, I display the bivariate relationships between the presence of taper laws 
and penalties and various state characteristics. States with higher drug-related overdose 
deaths were significantly more likely to enact a taper law (p<.001). These states were also 
more likely to enact a taper law with penalties (p=.007). I observed no relationship 
between taper laws and the Governor’s political affiliation nor with state population size 
or geographical location.  
 
Discussion 
 This was the first study to systematically review state tapering laws within the 
context of controlled substance prescribing for chronic pain. I found that over half of US 
states enacted at least one law that addressed opioid tapering and were frequently 
mentioned in the context of treatment agreements (data not shown). In the agreement, the 
prescriber often must include reasons for discontinuing or tapering an opioid prescription. 
For some states, the law might include an example such as violation of the contract. 
However, these laws often did not elaborate on what those violations were nor how to 
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taper the patient. Lack of instruction can be particularly problematic when laws are 
becoming instrumental in how we address the opioid epidemic (12, 82, 83).  Without 
explicit instructions for prescribers during a period of heavy scrutiny via prescription 
drug monitoring checks and morphine milligram equivalent limits, policymakers are 
limiting aspects of clinical judgment but not detailing the expected ways to transition 
patients into safer treatment options. Prior research suggests that lack of instruction 
regarding how clinicians should interpret guidelines could result in less useful 
interpretations that do not always benefit patients (84, 85). Additionally, lack of 
instruction further exacerbates a challenging situation for primary care providers. 
Providers often have insufficient time to address health concerns in a visit (36) but are 
now also expected to engage in an emotionally demanding conversation about beginning 
to taper and then how to safely continue (86).  
 I also found that among states with taper laws only two states cautioned against 
abruptly discontinuing. Currently, state laws provide little protection for patients when 
they need to be tapered off of a controlled substance. This gap leaves an already 
vulnerable population at the discretion of their healthcare provider who may or may not 
have the ability to provide tapering support or transition to a substance use specialist (86). 
Providers have identified several ways to facilitate tapering including supportive 
guidelines and policies, but there is little evidence that state laws are facilitating that need 
(86). Given these findings, policymakers should consider addressing this gap to minimize 
the risk of withdrawal, untreated pain, and suicide (26, 60). 
 Finally, I found that states with higher overdose death rates, as opposed to other 
state characteristics like political affiliation or geographic locations, were more likely to 
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enact a taper law and for their law to have a penalty. States with high opioid-related 
overdose death rates have more motivation to enact a policy that will decrease the 
number of opioids prescribed. However, states enacting these laws and those with 
penalties may place patients at a greater risk of abrupt tapering. Since these state laws 
mention tapering but generally lack patient protection from inappropriate ways or 
instances to taper, prescribers, in these states, may be more motivated to quickly reduce 
the number of opioids prescribed.  Additionally, stopping opioids may further contribute 
to overdose and suicide rates (87). These concerns warrant further investigation to 
understand the relationship between opioid prescribing and these preventable deaths. 
 
Limitations  
The current study has several limitations. First, the cross-sectional nature of these 
analyses is not suitable for casual inference, thus the findings can be interpreted as 
associations only. Second, the way I determined state policy concordance to the CDC 
guideline may not be comprehensive. I included twenty-four concepts from the CDC 
tapering pocket guide; however, the tapering pocket guide does not numerically label 
concepts. To the best of my ability, I worked to minimize interpretation and pull concepts 
nearly word for word from the guideline. Third, only one researcher was able to code the 
policies. As a result, the analysis could be subject to coding bias. However, I explain in 
detail how I generated the codes and make the definitions simple to reduce error. Last, 
although I attempt to capture all tapering laws, I may have missed some. To minimize 
missed laws, I completed a systematic search of all state laws that mention tapering a 
controlled substance and erred on the side of inclusion.  
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Conclusion 
 As of December 2019, most states have a law that mentions tapering but few 
address the bulk of the CDC’s tapering recommendations. Related to experts’ concerns 
(25), less than half of states with taper laws excluded more than one patient group and 
very few states cautioned against abrupt tapers or addressed how to handle inherited 
patients. Overall, most states do not address recommended tapering practices. This gap is 
concerning given our national goals to reduce opioid prescribing for those roughly 60 
million Americans with chronic pain (2). As this patient population transitions into other 
types of pain management, future research should explore what relationship if any 
tapering laws have on the health outcomes and cost implications for this population.  
Researchers should also explore what happens to patients once they are discontinued 
from opioid therapy and how policy might help bridge the treatment gap between opioid 




Table 3: Frequency of Opioid Taper Law Attributes in the United States  
Variable Number of States 
including DC with 
a tapering law 




N = 61 (100%) 
States with this attribute 
Law Type    
Regulation (written by 
entities granted this 
authority by legislative 
action) 
25 (89.2) 52 (85.2) AL, AZ, AR, DC, DE, IN, 
KY, LA, ME, MI, MN, 
MS, MO, NH, NJ, NM, 
OH, OK, PA, RI, TX, VT, 
VI, WA, WV 
Statutes (written by 
legislative bodies) 
9 (32.1) 9 (14.8) AZ, CT, FL, ME, NH, NJ, 




Medical boards 13 (46.4) 19 (31.1) AL, DE, IN, KY, ME, MS, 
NH, NJ, OH, OK, PA, TX, 
VA, WA 
Workers’ compensation 8 (28.5) 13 (21.3) AZ, AR, DE, LA, MI, OH, 
VT, WV 
Health department 4 (14.3) 9 (14.7) AZ, RI, VT, WA 
Occupational and 
professional board 
8 (28.5) 8 (13.1) CT, DC, FL, LA, NV, NH, 
NM, WA 
Department of Labor and 
Industry 
2 (7.1) 4 (6.5) MN, WA 
Medicaid Agency 2 (7.1) 3 (4.9) ME, MO 
State legislature 2 (7.1) 2 (3.3) PA, OK 
Other2 3 (10.7) 3 (4.9) DE, OK, NJ 
Penalty for 
noncompliance 
   
Yes 16 (57.1) 20 (32.8) AZ, AR, DE, ME, MI, 
MN, MO, NH, NM, OH, 
OK, RI, VT, WA, WV 
No 21 (75.0) 41 (67.2) AL, AZ, CT, DC, DE, FL, 
IN, LA, ME, MS, NV, NH, 
NJ, OH, OK, PA, TX, VT, 
VI, WA, WV 





denial, prior authorization) 
10 (62.5) 13 (65.0) AZ, AR, ME, MI, MN, 
MO, OH, VT, WA, WV 
Disciplinary action (revoke 
license, fine) 
5 (31.3) 6 (30.0) DE, KY, NH, NM, RI 
Criminal offense  1 (6.2) 1 (5.0) OK 
To whom the law applies     
Multiple provider types 22 (78.6) Not applicable AZ, CT, DC, DE, FL, IN, 
KY, ME, MN, MS, MO, 
NV, NH, NJ, OH, OK, PA, 
RI, VT, VI, WA, WV 
Nonspecific 8 (28.6) Not applicable AR, DE, LA, ME, OH, 
VT, WA, WV 
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Physicians or medical 
directors 
7 (25.0) Not applicable AL, AZ, LA, MI, OK, TX, 
WV 
Advanced practice 
registered nurse  
6 (21.4) Not applicable KY, NH, NM, TX, VI, WA 
Excluded Patient Groups    
No exclusions 21 (75.0) 37 (60.6) AL, AZ, AR, CT, DC, DE, 
IN, KY, LA, ME, MI, MN, 
MO, NV, NH, OK, PA, 
TX, VT, WA, WV 
More than one group 
excluded3 
11 (39.2) 16 (26.2) AZ, DE, KY, ME, NH, NJ, 
OH, OK, PA, VT, VI 
Cancer pain only 4 (14.2) 5 (8.2) FL, LA, NM, WV 
Palliative care only 3 (10.7) 3 (3.4) MS, OH, RI 
Note: This table does not include tapering policies related to substance use disorder 
treatment (i.e., medication assisted treatment, opioid treatment programs, office-based 
addiction treatment, substance abuse treatment programs, and addition co-prescribing). 
This table also excludes tapering policies related to scope of practice, pain clinics, 
hospice organizations, and skilled nursing facilities.   
1 States were often counted more than once per category because they had more than one 
tapering law.   
2 Other committees include the state bureau of narcotics and dangerous drugs control, 
controlled substance advisory committee, and dangerous substances and narcotic drugs. 
3 Excluded groups included some combination of the following: patients in long-term 
care facilities, receiving treatment for cancer, receiving hospice care, receiving palliative 
care, receiving pain treatment for sickle cell, receiving treatment in a clinical trial, 
receiving care as part of normal care at a hospital, or to any medications that are being 



















































Table 4. State with Laws that Are Concordant with CDC Taper Recommendation  
CDC Taper Recommendation State with Any 
Opioid Taper Laws 
N=28 (100%) 
Number of Individual Laws 
Across States that Address 
Opioid Tapering N=61 (100%) 
States with this 
attribute 
Suggested instances to taper 
1. When the patient requests a dosage 
reduction 
1 (3.6) 2 (3.3) WA 
2. When the patient does not have 
clinically meaningful improvement in 
pain and function 
7 (25.0) 12 (19.7) DE, LA, ME, OH, 
RI, WA, WV 
3. When on dosages ≥ 50 MME per day 
without benefit 
1 (3.6) 1 (1.6) KY 
4. When opioids are combined with 
benzodiazepines   
1 (3.6) 1 (1.6) KY 
5. When the patient shows signs of 
substance use disorder (e.g. work or 
family problems related to opioid use, 
difficulty controlling use) 
8 (28.6) 10 (16.4) DE, KY, LA, MN, 
RI, VT, WA, WV 
6. When the patient experiences overdose 
or other serious adverse event 
4 (14.3) 6 (9.8) KY, VT, WA, WV 
7. When the patient shows early warning 
signs for overdose risk such as confusion, 
sedation, or slurred speech 
0 (0.0) 0 (0.0) - 
Suggested ways to taper 
8. Develop an individualized tapering plan 
with the patient 
2 (7.1) 2 (3.3) MN, MO 
9. Minimize symptoms of opioid 
withdrawal while maximizing pain 







treatment with nonpharmacologic 
therapies and nonopioid medications 
    
10. Taper slowly 1 (3.6) 1 (1.6) KY 
11. Decrease of 10% per month if patients 
have taken opioids for more than a year 
0 (0.0) 0 (0.0) - 
12. Decrease of 10% per week if patients 
have taken opioids for a less than a year  
0 (0.0) 0 (0.0) - 
13. Discuss the risk of overdose if patients 
quickly return to a preciously prescribed 
higher dose 
0 (0.0) 0 (0.0) - 
14. Use extra caution for pregnant 
women1 
0 (0.0) 0 (0.0) - 
15. Use extra caution for patients with an 
opioid use disorder 
0 (0.0) 0 (0.0) - 
16. Offer psychosocial support, such as 
mental health providers, arrange for 
treatment of opioid use disorder, or offer 
naloxone for overdose prevention2 
0 (0.0) 0 (0.0) - 
17. Watch for signs of anxiety, 
depression, or opioid use disorder3 
0 (0.0) 0 (0.0) - 
18. Encourage the patient through the 
tapering process 
0 (0.0) 0 (0.0) - 
Taper Considerations 
19. Weigh the benefits and risks of opioid 
to make decision about whether to 
continue, reduce, or discontinue use 
19 (67.9) 32 (52.4) AL, AZ, DE, FL, 
KY, LA, ME, MN, 
MS, NH, NJ, NM, 








20. Caution against abrupt tapering or 
sudden discontinuation 
2 (7.1) 2 (3.3) KY, LA 
21. Adjust the rate and duration of the 
taper according to the patient’s response 
1 (3.6) 1 (1.6) MO 
22. Cautions against reversing a taper 0 (0.0) 0 (0.0) - 
23. Mentions that once the lowest 
available dose is reached the interval 
between doses can be extended 
0 (0.0) 0 (0.0) - 
24. Mentions how to manage inherited 
patients on opioids 
3 (10.7) 3 (4.9) ME, RI, WA 
1 While no laws discussed pregnant patients with respect to tapering, six states had laws that identified pregnant women as a 
vulnerable population requiring extra attention and possibly referral for chronic opioid prescribing.  
2 No laws stated offering psychosocial support in the context of tapering, but 14 states identified ways to provide psychosocial. 
3 No laws discussed watching for anxiety, depression, or opioid use disorder with respect to tapering; however, six states had 




Table 5. State Characteristics Associated with Taper Law(s) and Penalties (2014-
June 2017) 
 
 State has taper policy 
(Y/N) 
State has a taper policy 
with a penalty (Y/N) 









Opioid prescribing rate 
per 100 persons (mean) 
73.0 77.7 0.269 77.0 77.5 0.959 
Opioid-related 
overdose rate per 
100,000 persons (mean)  


































































































Since the 1990s, the increased rate of opioid prescribing has contributed to 
thousands of opioid related overdose deaths (45, 88). In response, the Centers for Disease 
Control and Prevention (CDC) released a set of opioid prescribing recommendations for 
primary care clinicians (33). Since the release of the CDC guideline, states have 
continued to enact laws and policies to decrease the amount of opioids prescribed. Two 
recent policies are morphine equivalent daily dose (MEDD) thresholds and acute pain 
prescription duration limits. Between 2014-2017, nineteen states enacted MEDD policies 
while 15 enacted acute opioid prescribing limit laws (14, 15). As states enact policies to 
reduce opioid prescribing, policymakers and researchers need to evaluate the effect of 
these laws on their intended outcomes.    
MEDD policies and laws that limit acute pain opioid prescribing both attempt to 
curb the amount of opioids prescribed by restricting different aspects of opioid 
prescriptions. MEDD policies set a limit by using a standard measurement, often referred 
to as milligrams morphine equivalent (MME) (89). MEDD policies determine a MME 
threshold at which a prescriber should stay below per day, ranging from 30-300 MEDD 
(14). Whereas, acute opioid limit prescribing laws focus on restricting the days supplied 




While some state laws are believed to affect opioid prescribing (12, 90-92), recent 
evidence has suggested that MEDD and acute pain limit laws are not associated with 
changes in opioid distribution across states (93) but acute pain limit laws increase initial 
opioid prescribing rates for new patients (94). Importantly, experts have called for more 
research on specific patient populations given that a broad analysis could mask 
population-specific effects of these laws (93) and a need to evaluate the effect of acute 
pain limits for longer than 3 months (94). One population, that may be sensitive to the 
effect of these laws, are patients with Medicaid, who are 3 to 6 times more likely to 
experience an opioid overdose (95). Additionally, patients with Medicaid have fewer 
nonopioid treatment options covered by their plans relative to commercial plans (96), 
which possibly places them at higher risk of uncontrolled pain. Lastly, while patients 
with Medicaid have received fewer opioids from 2012-2016 (97), little is known about 
the effect of these newer opioid prescribing policies on prescribing rates (93).  
The purpose of the current study is to determine the effect of MEDD and acute 
pain prescription duration limit laws on opioid prescribing rates for patients with 
Medicaid.  Moreover, I am interested in determining whether these laws have changed 
clinicians’ prescribing practices by examining changes in nonopioid pharmacologic 
treatments following enactment of state laws.  To accomplish these goals, I combine and 
utilize several published and publicly available datasets including an MEDD policy 
dataset from Heins et. al (14), an acute pain prescription limit law dataset from Davis et. 
al (15), Medicaid enrollee data, and the State Drug Utilization dataset.  Heins et. al and 
Davis et. al published policy surveillance datasets that include the date laws or policies 




state-level, Medicaid prescription drug information on prescription type, number of 
prescriptions, and amount paid. This study will be of interest to health researchers, 
healthcare clinicians, and policymakers who are interested in understanding whether 
these laws decreased opioid prescribing and how they might have changed medications 




For this study, I used generalized difference-in-difference models, which includes 
state and quarter time fixed effects. I used three and half years (2014 – June 2017) of 
state-quarter prescription drug utilization and reimbursement data from the Centers for 
Medicare and Medicaid Services’ (CMS) State Drug Utilization Dataset (SDUD). SDUD 
measures outpatient prescriptions, at least partially, paid for by Medicaid. Each quarter, 
the number of prescriptions, units reimbursed, amount paid, product name, and the 
national drug code number. While this does not measure all opioid prescribing to 
Medicaid patients, it is a good proxy for how many opioids were prescribed by clinicians 
and filled by patients. Specifically, this measure is a proxy measure for all prescriptions 
because a transaction is counted in SDUD only if a drug is dispensed and at least partially 
reimbursed. To calculate the number of prescriptions per enrollee, I used state Medicaid 
enrollee data available from CMS (98). Medicaid enrollee data is reported monthly and 
includes the state, expansion status, applications submitted, and total Medicaid 
enrollment. Two states (CA and ND) had a few quarters of enrollee data under review by 




these states did not have consecutive quarters under review and no more than 2 quarters 
under review in total, I imputed values for these quarters using the enrollee data in the 
quarter prior to and after the quarter under review.   
For the opioid prescribing policies, I used two publicly available policy 
surveillance datasets for MEDD (14) and acute pain prescription limit laws across states 
(15). The MEDD policy dataset includes state laws, prior authorizations, passive alert 
systems, and other state-level organization guidelines. The acute pain prescription limit 
law data set includes enactment date of the state law, duration limit, and medications 
covered.  
 To examine the effect of the opioid prescribing policies, MEDD and acute pain 
limits, I controlled for other state laws or policies known to influence opioid prescribing 
in the analyses. These laws include 1) requirements on prescribers to access the PDMP, 
2) legalized recreational marijuana, and 3) legalized medical marijuana. I obtained 
requirements regarding PDMP use from the National Alliance for Model State Drug 
Laws dataset and used in published research (94).  Medical marijuana laws were obtained 
from ProCon.org, a nonprofit public charity in Santa Monica, California. In addition to 
these law or policies, I controlled for whether a given state expanded their Medicaid 
program using expansion dates from the Kaiser Family Foundation. Medicaid expansion 
is known to have increased opioid prescribing and opioid addiction therapies after 
expansion (97). 
 To control for within state time varying characteristics, I captured several state 
economic measures that correlate with prescription opioid use and are commonly 




rate, and median household income from the US Census Bureau. I also included a 
variable to control for changes in prescribing across year quarters which might include 
seasonal patterns.  
 
Measures 
The primary outcome was the number of opioid prescriptions filled per Medicaid 
enrollee. I included 13 opioid medications including hydrocodone, oxycodone, codeine, 
buprenorphine, fentanyl, morphine, tramadol, meperidine, hydromorphone, methadone, 
pentazocine, tapentadol, and oxymorphone. The second outcome was prescription 
nonopioid medication rate per Medicaid enrollee and includes 12 nonopioid medications 
used to manage chronic pain: gabapentin, acetaminophen/butalbital, amitriptyline, 
desipramine, baclofen, duloxetine, nortriptyline, pregabalin, tylenol/butalbital, 
tylenol/butalbital/caffeine, amitriptyline, and celecoxib. This list was generated with the 
guidance of a board certified anesthesiologist and includes medications identified in 
previous work (100, 102-104). I used the publicly available national drug code (NDC) 
dataset from the Federal Drug Administration to identify these medications by their NDC 
number and identify these medications in the SDUD dataset.  
 
Statistical Analysis 
I used a generalized difference-in-difference design with state and quarter fixed 
effects to estimate the effect of MEDD and acute pain limit policies on opioid and 
nonopioid pain medication prescribing rates. The state fixed effects control for time 




affinity for deciding to adopt an opioid prescribing law. Quarter fixed effects control for 
seasonal characteristics that might influence the outcome variable such as the national 
release of the CDC’s opioid prescribing guideline. I also controlled for all the variables, 
described above, related to policies and state varying characteristics known to correlate 
with opioid prescribing.   
All difference-in-difference model estimates were generated from negative 
binomial fixed effect regressions. I used this approach because the outcome, number of 
prescriptions per Medicaid enrollee, was discrete integers and skewed toward 0.  All 
regressions were modeled as incident rate ratios. To estimate policy effects, I used the 
following expression: 
ln⁡(𝑅𝑥𝑠,𝑡) =  𝛽0 +  𝛽1𝑆𝑇𝑠 + 𝛽2𝑄𝑅𝑇𝑡 + 𝛽3𝑃𝑂𝐿𝐼𝐶𝑌𝑠,𝑡 + 𝜆𝐶𝑂𝑉𝑠,𝑡
+ 𝑙𝑛(𝑒𝑛𝑟𝑜𝑙𝑙𝑚𝑒𝑛𝑡𝑠,𝑡) + 𝜀𝑠,𝑡⁡ 
The coefficient for 𝑃𝑂𝐿𝐼𝐶𝑌𝑠,𝑡 estimates the effect of either MEDD policies or acute pain 
limit laws on prescribing rates. Depending on the model, I evaluated these policies 
separately and within the same model.  
To address fixed effect model assumptions, I evaluated the parallel trends 
assumption by visually plotting the outcomes overtime for states with and without 
MEDD policies and states with and without acute pain limit laws. I saw the number of 
prescriptions in the treatment and control groups were running in roughly parallel over 
the study period. To address strict exogeneity, another fixed effect model assumption that 
must be true to reduce estimation bias, I regressed the MEDD policies and acute pain 
limit laws on the model covariates. I found no covariates were significantly associated 




 In the main analysis, I estimated the effect of a new MEDD policy on the number 
of opioid and nonopioid prescriptions per Medicaid enrollee. A new MEDD policy is a 
MEDD law or guideline enacted during the observation period (2014-June 2017). Next, I 
estimated the effect of adding an additional new MEDD policy. For states that enacted 
more than one MEDD policy, I included a model to estimate the effect of one, two or 
more, and no MEDD policy on the number of prescriptions. Last, I estimated the effect of 
MEDD policy dose limits on prescribing rates. MEDD policies ranged from 30-300 
morphine milligrams equivalent a day. To determine the effect of more restrictive 
policies, I created two MEDD dose restriction categories: less than 100 MEDD per day 
and greater than or equal to 100 MEDD per day. Two states (AK and NY) enacted 
medical marijuana laws in the same quarter as a new MEDD policy. To eliminate 
collinearity and meet the strict exogeneity assumption, these two states were dropped 
from the MEDD analysis.  
 I similarly estimated the effect of acute pain limit laws on the number of opioid 
and nonopioid prescriptions per Medicaid enrollee. For these analyses, two states (ME 
and PA) were dropped because they enacted recreational marijuana and expanded 
Medicaid in the same quarter as a new MEDD policy, respectively.  
 
Sensitivity Testing 
I conducted sensitivity tests to further explore the relationship between opioid 
prescribing policies and prescribing rates. First, I explored the effect of lagging the 
independent policy variable if the policy was enacted in the second half of a quarter. 




19 MEDD policies between 2014 and June 2017 were enacted in the first month of the 
quarter. Similarly, only 8 out of 15 acute pain limit laws were enacted in the first month 
of the quarter. To better isolate the effect of these policies, I delayed the intervention 
quarter by 1 period when a state enacted a policy in the second half of the quarter (see 
Appendix A). Appendix B includes a list of the states included in the analyses. 
 
Results 
In Table 6 are the descriptive statistics of key variables including independent, 
dependent, and control variables. During the study period, eighteen states enacted MEDD 
policies and 15 states enacted acute pain limit laws. States also enacted mandatory PDMP 
laws (n=24), medical marijuana laws (n=31), recreational marijuana laws (n=9), and 
expanded their Medicaid program (n=31).  During the study period, opioids were 
prescribed at a higher rate (13.2 per 100 enrollees) than nonopioid drugs (6.3 per 100 
enrollees).  
Figure 3 displays state pain medication prescribing rates in states with a MEDD 
or acute pain limit policy. Opioid prescribing rates decreased over time in states with a 
MEDD or acute pain limit law. States with MEDD policies appeared to have a slightly 
lower prescribing rate over time than control states, whereas states with an acute pain 
limit law had prescribing rates about the same as control states. For nonopioid prescribing 
rates, I observed an increase in the number of prescriptions per enrollee over time for 
both treatment and control states.   
In Table 7 are the regression results for the effect of MEDD policies on pain 




estimate for the effects of a new MEDD policy, shows a significantly decreased incident 
rate of opioid prescriptions (IRR=0.92; CI=0.87, 0.98). Model 2 estimates the effect of 
enacting one or more MEDD policies while controlling for other variables and shows a 
significant decline in the incident rate of opioid prescriptions once a new MEDD policy 
(IRR=0.92; CI=0.86, 0.97) is enacted. In Model 3, we observe a significant decrease in 
the number of opioid prescriptions when a state enacts an MEDD law with a limit greater 
than or equal to 100 MEDD relative to control states (IRR=.91; CI=0.83, 0.99). In the 
sample, nine states enacted a MEDD policy equal to or above 100 MEDD while 7 
enacted a MEDD policy below 100 MEDD.  Models 4-6 present the difference-in-
difference estimates for the effect of MEDD policies on nonopioid prescriptions. Model 4 
shows no significant change in the number of nonopioid prescriptions per Medicaid 
enrollee. Similarly, this finding is consistent in Model 5, which estimates the effect of 
adding one or more MEDD policies on nonopioid prescribing. In Model 6, we also 
observe no significant change in nonopioid prescribing related to MEDD dose limit.   
Table 8 displays the difference-in-difference regression results for the effects of 
acute pain limit laws on pain medication prescribing. Model 1, which includes the control 
variables, shows a significant decrease in the number of opioid prescriptions when an 
acute pain limit law is enacted (IRR=0.85; CI=0.79, 0.91). In Model 2 we observed no 
significant change in the number of nonopioid prescriptions.  
The results of the sensitivity analyses are presented in Appendix A. Appendix A 
includes regression results for the estimated lagged effect of a new MEDD policy or 
acute pain limit law on pain medication rates. Appendix A largely supports the main 




CI=.85, .96) for MEDD policies and acute pain limit laws (IRR=0.81; CI=0.74, 0.88).  




 MEDD policies and acute pain limit laws were both associated with a decrease in 
the number of opioid prescriptions filled per Medicaid enrollee. These associations were 
consistent across all of the sensitivity tests. MEDD policies are mainly intended to focus 
upon decreasing the morphine milligram equivalent per day prescribed to patients with 
chronic pain. For chronic pain patients, these findings suggest that clinicians may be 
responding to the policies by tapering patients off opioid therapy, prescribing opioids less 
often, or no longer starting patients on long-term opioid therapy. Previous studies found 
MEDD policies were associated with decreases in the MEDD of opioids in a single state 
study and in the workers’ compensation population (83, 105). However, total opioid 
prescriptions appear to be affected and may be problematic. One particularly difficult 
change may be opioid tapering which is challenging for clinicians and patients and can 
result in terminated care (51, 106). Without a standardize way to transition patients off 
opioid therapy and stronger evidence of the long-term effectiveness and accessibility of 
nonopioid treatments (107, 108), more research is need to understand if there is an 
unintended consequence of MEDD polices.   
Acute pain limit laws were also associated with reductions in the number of 
opioid prescriptions filled by Medicaid enrollees. Acute pain limit laws focus on 




acute pain.  The results suggest that clinicians, in states with these policies, may be 
prescribing fewer opioids than previous when compared to control states. In previous 
studies, acute pain limit laws’ were not associated with a change in the volume of 
morphine gram equivalents distributed (93), but they were associated with an increase in 
the number of initial prescriptions to new opioid users (94). If the number of initial 
prescriptions to new opioid users is increasing, then the results may not be measuring a 
prescribing changing for patients with acute pain. This distinction warrants further 
investigation to understand the effects of acute pain limit policies, especially given recent 
concern that clinical prescribing guidelines may be misapplied in clinical practice (25, 26, 
50).  
The secondary finding was that both MEDD and acute pain limit policies were 
not associated with a significant change in nonopioid pain medication prescribing. Most 
MEDD policies exclude opioid prescribing for patients with terminal, acute, and cancer 
pain (14), Given these policies do not exclude patients with chronic pain, these findings 
suggest that patients may not be receiving additional nonopioid pharmacologic 
prescriptions to manage their pain while the number of opioid prescriptions declines. The 
CDC opioid prescribing guideline and tapering guide for chronic pain suggests using 
nonopioid treatments to manage patients’ pain while they are reduced to safer MEDD 
limits or are discontinued from opioid therapy (33, 70). Given declines in the number of 
prescriptions written and insignificant rise of nonopioid pharmacologic prescriptions, 
researchers should attempt to identify what alternative treatments patients are receiving.  
Acute pain limit laws were also not associated with a change in nonopioid pain 




pain, acute pain limit laws target patients with acute pain. And while this study did not 
capture all possible treatment alternatives to nonopioid prescriptions, no significant 
change in nonopioid prescriptions suggests that patients may not be receiving more 
pharmacologic nonopioid pain medications despite the observed reduction in number of 
opioid prescriptions.  Given the constrained nonopioid treatment options patients with 
Medicaid face and primary care clinicians high refusal to treat patients with opioids (96, 
109), further investigation is needed to understand what treatments, beyond opioids, these 
patients with chronic and acute pain receive.  
 
Limitations 
First, this study cannot differentiate opioid prescribing for acute and chronic pain. 
Ideally, we would want to isolate the effect of these policies on the type of pain they are 
expected to treat or unintentionally to influence. I recommend future research to explore 
the effect of these policies on acute and chronic pain individually to determine if clinical 
misapplication occurs.  Second, I was unable to measure the effects of these laws on 
MEDD prescriptions or the number of days supplied. The SDUD data includes NDCs; 
however, NDCs do not include the number of days a prescription is to be taken. As a 
result, future research should attempt to understand the effect of these laws with full 
prescription information for patients with Medicaid. Third, I was unable to control for 
other factors that might influence the outcomes such as mandatory pharmaceutical PDMP 
checks, patients not able to fill or collect a prescription, etc. Thus, these and other omitted 
variables may bias the regression results. Fourth, SDUD data is suppressed when 11 or 




medication. For example, if only 3 prescriptions were written for meperidine in New 
Mexico in quarter 3 of 2014, then that medication did not have a recorded value and is 
blank. Although this is not a large amount of missing medications, this limitation may 
under count certain prescription medications. Finally, the results from this analysis are 
not generalizable beyond the Medicaid population.  
 
Conclusion 
 I found that states with either MEDD policies or acute pain limit laws reduced 
their opioid prescriptions per Medicaid enrollee compared to states without these policies. 
This suggests current policies may not be written with enough specificity to minimize 
unintended effects. Both of these policies target limiting a specific aspect of opioid 
prescribing doses, the morphine milligram equivalent daily dose and the number of days 
supplied. However, both policies appear to influence the number of total opioid 
prescriptions written and filled for patients with Medicaid. Additionally, while these 
policies are associated with fewer opioid prescriptions, they are not associated with 
increased nonopioid medications. The findings from this study suggest policy researchers 
do not have a complete understanding of how state policies are influencing medication 
prescribing and that exploring those relationships deserves further attention. These 
findings also encourage additional exploration about recent concerns of clinical 
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Table 6. State Covariates and Prescription Outcomes 






# of states with MEDD policies 22 (43.1%) 213 (29.8%) 
# of states with acute pain laws  19 (37.3%) 91 (12.7%) 
# of states with New MEDD policies during study period 
(2014-June 2017)1 
 



























# of states with acute pain laws during study period 
(2014-June 2017) 2 
13 (25.5%) 31 (4.3%) 
# of opioid Rx per quarter 152,972 (171,640) NA 
Opioid Rx per 100 enrollees per quarter 12.2 (4.4) NA 
# of nonopioids Rx per quarter 83,057 (99,937) NA 
Non-Opioid Rx per 100 enrollees per quarter 6.3 (2.7) NA 
Poverty rate 14.1 (3.1) NA 
Median household income  $56,898.25 ($9,670.86) NA 
Unemployment rate 5.0 (.01) NA 
PDMP law 24 (47.0%) 226 (31.7%) 
Legal marijuana 9 (17.6%) 64 (8.9%) 
Medical marijuana 31 (60.8%) 355 (49.7%) 
Medicaid expansion 31 (60.8%) 399 (55.9%) 








2 Two states (ME and PA) were excluded from the analysis because they enacted another policy in the same quarter as the 







Table 7. Fixed Effect Negative Binomial Regression Results for the Effects of MEDD Policies on the Number of Pain 
Medication Prescriptions per Medicaid Enrollee: United States, 2014 – June 2017 
 
 Dependent variable: number of opioid 
prescriptions per Medicaid Enrollee 
Dependent variable: number of nonopioid 
prescriptions per Medicaid Enrollee 
Variable Model 1, 
IRR (95% 
CI) 
Model 2, IRR 
(95% CI) 
Model 3, IRR 
(95% CI) 
Model 4, IRR 
(95% CI) 
Model 5, IRR 
(95% CI) 
Model 6, IRR 
(95% CI) 
New medd policy1 .92* (.87, 
.98) 
  .98 (.93, 1.04)   
# of new medd 
policies2 










   
 
Reference 
.98 (.93, 1.04) 
.98 (.90, 1.06) 
 
New MEDD 
policy by dose 
No New MEDD 
<100 MEDD 
≥100 MEDD 
   
Reference 
.93 (.96, 1.01) 
.91* (.83, .99) 






























































.97 (.88, 1.07) .97 (.87, 1.07) .97 (.88, 
1.07) 




































.90*** (.87, .93) .90*** (.87, .93) .90*** (.87, 
.93) 
* <.05    
**<.01    
***<.001 
1 This measure captures the effect of any new medd policy enacted during the intervention period.  















Table 8. Fixed Effect Negative Binomial Regression Results for the Effects of Acute Pain Laws on the Number of Pain 
Medication Prescriptions per Medicaid Enrollee: United States, 2014 – June 2017 
 
 Dependent variable: number of 
opioid prescriptions per Medicaid 
Enrollee 
Dependent variable: number of 
nonopioid prescriptions per 
Medicaid Enrollee 
Variable Model 1, IRR (95% CI) Model 2, IRR (95% CI) 
Acute pain limit law .85*** (.79, .91) 1.03 (.97, 1.09) 
Seasonality 1.01* (1.00, 1.03) 1.03*** (1.01, 1.04) 
PDMP law .89** (.82, .96) .94 (.88, 1.01) 
Medical marijuana law .94 (.88, 1.01) 1.01 (.93, 1.09) 
Rec marijuana law 1.05 (.97, 1.14) 1.17*** (1.10, 1.24) 
Medicaid expansion 1.07 (.96, 1.20) .97 (.86, 1.10) 
Poverty rate .92*** (.88, .96) .94*** (.91, .98) 
Median household income  .99*** (.99, .99) 1.00* (1.00, 1.00) 
Unemployment rate .93*** (.30, .96) .92*** (.89, .95) 
* <.05    













Over the past two decades, overdoses involving opioids have taken the lives of 
nearly half a million Americans (110). As one response to the opioid epidemic, the CDC 
published a set of opioid prescribing recommendations for primary care clinicians 
detailing how and when to prescribe opioids for patients with chronic nonmalignant pain. 
Among these recommendations, the CDC guideline included topics to discuss in clinic 
visits and recommended prescribing thresholds at which to exercise caution.(33) The 
CDC also released a set of opioid prescribing considerations related to tapering a patient 
off of long-term opioid therapy (70). 
Since the release of the CDC guideline, overdose rates involving prescription 
opioids have leveled off and started to decline (111). However, medical experts and 
federal agencies have voiced concern about their application in policy and clinical 
practice (25, 26, 50). To better understand whether these concerns are warranted, this 
dissertation examined how some of these federal recommendations were implemented in 
clinic practice and state law, as well as the effects of prescribing laws related to 
prescribing thresholds.  
Overall, this dissertation attempts to understand the translation of national opioid 
prescribing guidelines into policy and their effects on healthcare delivery. I sought to 
understand how elements of the CDC guideline are adopted into clinical practice, state 
policy, and establish the downstream effects of two state policies on prescribing behavior. 
The purpose of this dissertation was to garner knowledge on how clinicians and states 




and with these findings, inform the development of future guidelines and minimize the 
risk of misinterpretation across the structural and procedural aspects of healthcare 
delivery (112).  
To address these interests, this dissertation included three studies 1) a qualitative 
analysis of clinician and patient discussions about opioid-related risks, benefits, and 
treatment goals, 2) a policy surveillance study of state tapering laws and their consistency 
with the CDC guideline’s opioid tapering recommendations, and 3) an empirical study of 
the effects of morphine milligram equivalent daily dose laws and acute opioid prescribing 
laws on pain medication prescribing for patients with Medicaid.   
 Chapter two examined clinician and patient communication about opioid-related 
risks, benefits, and treatment goals with the intent on understanding how similarly, if at 
all, clinical practice mirrored the information from the CDC guideline. I observed several 
encouraging themes during these discussions. First, clinicians discussed opioid-related 
risks with their patients in two ways.  Clinicians presented risks at an individual and 
population-level manner. The individual-level risk discussions focused on patient specific 
health concerns of using opioid therapy. On the other hand, population-level risk 
discussions referenced population statistics related to opioid overdose deaths. Second, I 
observed clinicians convey the limited effectiveness of opioid therapy, instructing 
patients that these medications were not long-term solutions to pain management and did 
not treat the underlying cause of the pain. Finally, I found clinicians discussed the use of 
nonopioid therapies as better alternatives to managing pain symptoms including within 




These results are encouraging in that clinicians are discussing the risks and 
limitations of opioid therapy with their patients while introducing nonopioid therapies to 
control pain. However, the use of population-level risk discussions may not best serve the 
patient like an individualized risk discussion.(51)  Given these findings, the discussions 
in clinical practice are generally concordant with the discussion-based aspects of the 
CDC guideline with one exception. The CDC guideline does not provide structured 
advice of how to best communicate risk to patients. As a recommendation for future 
policy, I suggest federal and state policymakers be more explicit about how clinicians 
should share information with patients given the most up-to-date evidence available. 
Policymakers should wield this information to ensure a less varied delivery of 
information to patients.  
 Chapter three focused on identifying and articulating the variation in state 
tapering policy related to opioid prescribing.  I found over half of states enacted at least 
one law that mentioned opioid tapering, often in the context of an opioid treatment 
agreement. However, these laws did not provide instruction around how to taper nor 
consistently identify when to discontinue treatment. Importantly, I also found that only 
two states cautioned against abruptly discontinuing, an established concern with long-
term opioid use. Last, I observed that states with high overdose death rates were more 
likely to enact a taper law and for those laws to have a penalty.  
Overall, these findings suggest that policymakers may not consult with the CDC 
guideline to model their policy or have not yet recognized the importance of 
acknowledging evidence-based tapering practices. Provided the CDC guideline does not 




recommendations were scarcely represented across state laws. With federal and expert 
concerns about abrupt opioid discontinuation (25, 26, 50), my work suggests that 
policymakers should take notice of these discrepancies and provide more evidence-based 
tapering recommendations in their policy. As I expected, states with higher overdose 
death rates were more likely to have a taper law and a penalty. This finding is particularly 
worrisome, because these laws do not provide much guidance around tapering procedures 
and yet require compliance. Further, these states may have a greater population at risk of 
being incorrectly tapered from opioid therapy. Based on these findings, I recommend 
state policymakers take notice of the CDC’s tapering pocket guide and other evidence-
based tapering recommendations to ensure safer tapering for this patient population.  
 Chapter 4 evaluated the effect of two opioid prescription limit laws on pain 
medication prescriptions for patients with Medicaid. Overall, I found MEDD policies and 
acute opioid limit laws decreased the number of opioids prescribed. I also observed no 
significant change in the number of nonopioid prescriptions when a state enacted one of 
these policies, despite the reduction in opioid prescriptions.  
These findings suggest prescribing threshold policies may be contributing to 
overall declines in the number of opioid prescriptions, meanwhile not increasing the 
number of nonopioid prescriptions. Declines in opioid prescriptions may be an 
unintended effect of these laws that warrants further investigation across different patient 
populations. The second finding, no significant change in nonopioid prescriptions, also 
warrants further investigation. As I learned from chapter 2, clinicians often discussed 
with patients the use of nonopioid prescriptions as a means of treating pain while 




investigation into the potential unintended effects of these laws and study of how pain is 
managed, if at all. Future studies should also identify and explore how these patients are 
discontinued from opioid therapy and what their treatment involves.  
 When considered cumulatively, these findings illuminate both strengths and 
weaknesses of the US’s reaction to federal policy from policymakers to healthcare 
professionals. Among those strengths, I observed clinicians convey the risks and 
limitations of opioid therapy, state policymakers introduce the need for treatment 
agreements and tapering as a consequence of not upholding those agreements, and over 
half of states have at least some language or guidance around opioid tapering. However, 
the US also has an opportunity to improve its response to federal guidelines, for the 
opioid epidemic and all future national crises.  
In addition to the above-mentioned recommendations, I believe federal guideline 
authors would benefit from using more precise language to clearly articulate the intention 
of the guideline to address the opioid epidemic. With a clear goal and understanding in 
mind, policymakers, health administrators, and clinicians should be equipped to actualize 
the more detailed nuances of the guideline and minimize misapplication and 
interpretation of them. Second, I believe federal guidelines should anticipate the 
outcomes of their recommendations by carefully considering the future for all parties 
involved such as how patients with chronic pain might be treated, how policymakers 
might interpret the guideline, etc. Finally, I believe how the US addressed the epidemic 
deserves considerable attention in order to improve our ability to address future public 








Appendix A. Lagged Analysis – Fixed Effect Negative Binomial Regression Results 
Lagged Analysis – Fixed Effect Negative Binomial Regression Results for the Effects of MEDD Policies and Acute pain limit laws on the 
Number of Pain Medication Prescriptions per Medicaid Enrollee: United States, 2014 – June 2017 
 Dependent variable: number of opioid 
prescriptions per Medicaid Enrollee 
Dependent variable: number of nonopioid 
prescriptions per Medicaid Enrollee 
Variable Model 1, IRR (95% 
CI) 
Model 2, IRR (95% 
CI) 
Model 3, IRR (95% 
CI) 
Model 4, IRR (95% 
CI) 
New MEDD policy1 .91** (.85, .96)  .97 (.92, 1.03)  
Acute pain limit law  .81*** (.74, .88)  1.01 (.95, 1.08) 
Seasonality 1.01 (.99, 1.02) 1.01* (1.00, 1.03) 1.03*** (1.02, 1.04) 1.03*** (1.01, 1.04) 
PDMP law .90** (.83, .97) .89** (.82, .96) 1.00 (.93, 1.06) .95 (.88, 1.01) 
Medical marijuana law .97 (.91, 1.04) .94 (.88, 1.01) 1.22*** (1.14, 1.31) 1.01 (.93, 1.09) 
Rec marijuana law 1.06 (.98, 1.14) 1.05 (.98, 1.14) 1.16*** (1.10, 1.22) 1.16*** (1.09, 1.24) 
Medicaid expansion 1.07 (.98, 1.17) 1.07 (.96, 1.19) .97 (.88, 1.07) .97 (.86, 1.10) 
Poverty rate .90***(.87, .94) .91*** (.88, .95) .99 (.96, 1.03) .95** (.91, .99) 
Median household income .99*** (.99, .99)  .99*** (.99, .99) 1.00*** (1.00, 1.00) 1.00** (1.00, 1.00) 
Unemployment rate .92*** (.89, .95) .93*** (.90, .96) .90*** (.87, .93) .92*** (.89, .95) 
* <.05    
**<.01    
***<.001 















Appendix B. States with MEDD or Acute Pain Policies 
States with MEDD or acute pain policies included in the analysis and enacted during the study period, 2014 – June 2017 












States with new MEDD polices 
N=16 
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